Roche’s Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer |
Roche RHHBY announced that the FDA has approved a label expansion for Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)…
Roche’s Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer
Roche RHHBY announced that the FDA has approved a label expansion for Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)…
Roche’s Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer
Roche RHHBY announced that the FDA has approved a label expansion for Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)…
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
F. Hoffmann-La Roche Ltd Basel, 13 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that…